Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges

References

• HanahanDWeinbergRAThe Hallmarks of CancerCell20001001577010647931
   PubMed Web of Science ®Google Scholar
• TorchilinVPDrug targetingEur J Pharm Sci200011Suppl 2S81S9111033430
   PubMed Web of Science ®Google Scholar
• MuroSChallenges in design and characterization of ligand-targeted drug delivery systemsJ Control Release2012164212513722709588
   PubMed Web of Science ®Google Scholar
• LammersTKiesslingFHenninkWEStormGDrug targeting to tumors: principles, pitfalls and (pre-) clinical progressJ Control Release2012161217518721945285
   PubMed Web of Science ®Google Scholar
• KiesslingAWehnerRFusselSBachmannMWirthMPSchmitzMTumor-associated antigens for specific immunotherapy of prostate cancerCancers20124119321724213236
   PubMedGoogle Scholar
• ZhangLLiYYuJCChemical modification of inorganic nanostructures for targeted and controlled drug delivery in cancer treatmentJ Mater Chem B201425452470
   Web of Science ®Google Scholar
• PeerDKarpJMHongSFarokhzadOCMargalitRLangerRNanocarriers as an emerging platform for cancer therapyNat Nanotechnol200721275176018654426
   PubMed Web of Science ®Google Scholar
• BertrandNWuJXuXKamalyNFarokhzadOCCancer nanotechnology: the impact of passive and active targeting in the era of modern cancer biologyAdv Drug Deliv Rev20146622524270007
   PubMed Web of Science ®Google Scholar
• ParnhamMJWetzigHToxicity screening of liposomesChem Phys Lipids1993641–32632748242838
   PubMed Web of Science ®Google Scholar
• MarkmanJLRekechenetskiyAHollerELjubimovaJYNanomedicine therapeutic approaches to overcome cancer drug resistanceAdv Drug Deliv Rev20136513–141866187924120656
   PubMed Web of Science ®Google Scholar
• KopecekJPolymer-drug conjugates: origins, progress to date and future directionsAdv Drug Deliv Rev2013651495923123294
   PubMed Web of Science ®Google Scholar
• WuJHuangWHeZDendrimers as carriers for siRNA delivery and gene silencing: a reviewScientific World Journal20132013630654
   Google Scholar
• KumarNRavikumarMNDombAJBiodegradable block copolymersAdv Drug Deliv Rev2001531234411733116
   PubMed Web of Science ®Google Scholar
• SosnikACarcabosoAMNanomedicines in the future of pediatric therapyAdv Drug Deliv Rev20147314016124819219
   PubMed Web of Science ®Google Scholar
• AngeloniVTiberioPAppiertoVDaidoneMGImplications of stemness-related signaling pathways in breast cancer response to therapySemin Cancer Biol Epub8182014
   Web of Science ®Google Scholar
• ReichertJMRosensweigCJFadenLBDewitzMCMonoclonal antibody successes in the clinicNat Biotechnol20052391073107816151394
   PubMed Web of Science ®Google Scholar
• WeeraratneDChenAPennucciJJImmunogenicity of panitumumab in combination chemotherapy clinical trialsBMC Clin Pharmacol2011111722070868
   PubMedGoogle Scholar
• RiechmannLClarkMWaldmannHWinterGReshaping human antibodies for therapyNature198833261623233273127726
   PubMed Web of Science ®Google Scholar
• WeinerLMSuranaRWangSMonoclonal antibodies: versatile platforms for cancer immunotherapyNat Rev Immunol201010531732720414205
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govPart 2 of Phase 1 Study of GC1008 to Treat Advanced Melanoma (Part 2 Will Only Accept and Treat Patients With Advanced Malignant Melanoma) Available from: http://clinicaltrials.gov/ct2/show/results/NCT00899444Accessed November 14, 2014
   Google Scholar
• PinesGKostlerWJYardenYOncogenic mutant forms of EGFR: lessons in signal transduction and targets for cancer therapyFEBS Lett2010584122699270620388509
   PubMed Web of Science ®Google Scholar
• SchlessingerJCell signaling by receptor tyrosine kinasesCell2000103221122511057895
   PubMed Web of Science ®Google Scholar
• SchlessingerJSignal transduction. Autoinhibition controlScience2003300562075075212730587
   PubMedGoogle Scholar
• DawsonJPBergerMBLinCCSchlessingerJLemmonMAFergusonKMEpidermal growth factor receptor dimerization and activation require ligand-induced conformational changes in the dimer interfaceMol Cell Biol200525177734774216107719
   PubMed Web of Science ®Google Scholar
• LeahyDJA molecular view of anti-ErbB monoclonal antibody therapyCancer Cell200813429129318394550
   PubMed Web of Science ®Google Scholar
• HolbroTHynesNEErbB receptors: directing key signaling networks throughout lifeAnnu Rev Pharmacol Toxicol20044419521714744244
   PubMed Web of Science ®Google Scholar
• HerbstRSShinDMMonoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapyCancer20029451593161111920518
   PubMed Web of Science ®Google Scholar
• SchmitzKRBagchiARooversRCvan Bergen en HenegouwenPMFergusonKMStructural evaluation of EGFR inhibition mechanisms for nanobodies/VHH domainsStructure20132171214122423791944
   PubMed Web of Science ®Google Scholar
• FelderSLaVinJUllrichASchlessingerJKinetics of binding, endocytosis, and recycling of EGF receptor mutantsJ Cell Biol199211712032121556153
   PubMed Web of Science ®Google Scholar
• LowKWackerMWagnerSLangerKvon BriesenHTargeted human serum albumin nanoparticles for specific uptake in EGFR-Expressing colon carcinoma cellsNanomedicine20117445446321215330
   PubMed Web of Science ®Google Scholar
• BenhabbourSRLuftJCKimDIn vitro and in vivo assessment of targeting lipid-based nanoparticles to the epidermal growth factor-receptor (EGFR) using a novel Heptameric ZEGFR domainJ Control Release20121581637122037106
   PubMed Web of Science ®Google Scholar
• MicklerFMMocklLRuthardtNOgrisMWagnerEBrauchleCTuning nanoparticle uptake: live-cell imaging reveals two distinct endocytosis mechanisms mediated by natural and artificial EGFR targeting ligandNano Lett20121273417342322632479
   PubMed Web of Science ®Google Scholar
• DanceyJEPredictive factors for epidermal growth factor receptor inhibitors–the bull’s-eye hits the arrowCancer Cell20045541141515144948
   PubMed Web of Science ®Google Scholar
• BurgessAWEGFR family: structure physiology signalling and therapeutic targetsGrowth Factors200826526327418800267
   PubMed Web of Science ®Google Scholar
• WikstrandCJHaleLPBatraSKMonoclonal antibodies against EGFRvIII are tumor specific and react with breast and lung carcinomas and malignant gliomasCancer Res19955514314031487606735
   PubMed Web of Science ®Google Scholar
• BardelliAJannePAThe road to resistance: EGFR mutation and cetuximabNat Med201218219920022310681
   PubMed Web of Science ®Google Scholar
• BierHReiffenKAHaasIStasieckiPDose-dependent access of murine anti-epidermal growth factor receptor monoclonal antibody to tumor cells in patients with advanced laryngeal and hypopharyngeal carcinomaEur Arch Otorhinolaryngol199525274334398562040
   PubMed Web of Science ®Google Scholar
• YangXDJiaXCCorvalanJRWangPDavisCGDevelopment of ABX-EGF, a fully human anti-EGF receptor monoclonal antibody, for cancer therapyCrit Rev Oncol Hematol2001381172311255078
   PubMed Web of Science ®Google Scholar
• DienstmannRFelipENecitumumab in the treatment of advanced non-small cell lung cancer: translation from preclinical to clinical developmentExpert Opin Biol Ther20111191223123121679088
   PubMed Web of Science ®Google Scholar
• LiSSchmitzKRJeffreyPDWiltziusJJKussiePFergusonKMStructural basis for inhibition of the epidermal growth factor receptor by cetuximabCancer Cell20057430131115837620
   PubMed Web of Science ®Google Scholar
• MeiraDDNobregaIde AlmeidaVHDifferent antiproliferative effects of matuzumab and cetuximab in A431 cells are associated with persistent activity of the MAPK pathwayEur J Cancer20094571265127319167213
   PubMed Web of Science ®Google Scholar
• SaltzLEasleyCKirkpatrickPPanitumumabNat Rev Drug Discov200651298798817201026
   PubMed Web of Science ®Google Scholar
• ImaiKTakaokaAComparing antibody and small-molecule therapies for cancerNat Rev Cancer20066971472716929325
   PubMed Web of Science ®Google Scholar
• LiSKussiePFergusonKMStructural basis for EGF receptor inhibition by the therapeutic antibody IMC-11F8Structure200816221622718275813
   PubMed Web of Science ®Google Scholar
• SchmiedelJBlaukatALiSKnochelTFergusonKMMatuzumab binding to EGFR prevents the conformational rearrangement required for dimerizationCancer Cell200813436537318394559
   PubMed Web of Science ®Google Scholar
• VanhoeferUTewesMRojoFPhase I study of the humanized antiepidermal growth factor receptor monoclonal antibody EMD72000 in patients with advanced solid tumors that express the epidermal growth factor receptorJ Clin Oncol200422117518414701780
   PubMed Web of Science ®Google Scholar
• ClynesRATowersTLPrestaLGRavetchJVInhibitory Fc receptors modulate in vivo cytotoxicity against tumor targetsNat Med20006444344610742152
   PubMed Web of Science ®Google Scholar
• AgusDBAkitaRWFoxWDTargeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growthCancer Cell20022212713712204533
   PubMed Web of Science ®Google Scholar
• CapelanMPuglianoLDe AzambujaEPertuzumab: new hope for patients with HER2-positive breast cancerAnn Oncol201324227328222910839
   PubMed Web of Science ®Google Scholar
• BaselgaJAlbanellJMechanism of action of anti-HER2 monoclonal antibodiesAnn Oncol200112Suppl 1S35S4111521720
   PubMedGoogle Scholar
• RoskoskiRJrThe ErbB/HER receptor protein-tyrosine kinases and cancerBiochem Biophys Res Commun2004319111115158434
   PubMed Web of Science ®Google Scholar
• MolinaMACodony-ServatJAlbanellJRojoFArribasJBaselgaJTrastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cellsCancer Res200161124744474911406546
   PubMed Web of Science ®Google Scholar
• ShaughnessyAFMonoclonal antibodies: magic bullets with a hefty price tagBMJ2012345e834623236036
   PubMed Web of Science ®Google Scholar
• MazarAPAhnRWO’HalloranTVDevelopment of novel therapeutics targeting the urokinase plasminogen activator receptor (uPAR) and their translation toward the clinicCurr Pharm Des201117191970197821711234
   PubMed Web of Science ®Google Scholar
• NykjaerAConeseMChristensenEIRecycling of the urokinase receptor upon internalization of the uPA:serpin complexesEMBO J19971610261026209184208
   PubMed Web of Science ®Google Scholar
• WyrozumskaPMToporkiewiczJSzarawarskaMLiposome-coated lipoplex–based carrier for antisense oligonucleotidesCancer Biol Ther Epub11202014
   Web of Science ®Google Scholar
• GongRChenWDimitrovDSExpression, purification, and characterization of engineered antibody CH2 and VH domainsMethods Mol Biol20128998510222735948
   PubMedGoogle Scholar
• MillerKRKoideALeungBT cell receptor-like recognition of tumor in vivo by synthetic antibody fragmentPLoS One201278e4374622916301
   PubMed Web of Science ®Google Scholar
• HolligerPHudsonPJEngineered antibody fragments and the rise of single domainsNat Biotechnol20052391126113616151406
   PubMed Web of Science ®Google Scholar
• Savage LaboratoriesCroFab^®-The primary pit viper antivenom treatment in the United States for more than 13 years Available from: http://www.savagelabs.com/index.htmAccessed November 14, 2014
   Google Scholar
• Drugs.comAblynx’s Partner Boehringer Ingelheim Initiates Phase I Study With Nanobody to Treat Alzheimer’s Disease Available from: http://www.drugs.com/clinical_trials/ablynx-s-partner-boehringer-ingelheim-initiates-phase-study-nanobody-alzheimer-s-16281.htmlAccessed October, 2013
   Google Scholar
• SmithGPPetrenkoVAPhage DisplayChem Rev199797239141011848876
   PubMed Web of Science ®Google Scholar
• KoivunenEArapWRajotteDLahdenrantaJPasqualiniRIdentification of receptor ligands with phage display peptide librariesJ Nucl Med199940588388810319765
   PubMed Web of Science ®Google Scholar
• MarascoDPerrettaGSabatellaMRuvoMPast and future perspectives of synthetic peptide librariesCurr Protein Pept Sci20089544746718855697
   PubMed Web of Science ®Google Scholar
• LeeTYLinCTKuoSYChangDKWuHCPeptide-mediated targeting to tumor blood vessels of lung cancer for drug deliveryCancer Res20076722109581096518006841
   PubMed Web of Science ®Google Scholar
• BrownKCNew approaches for cell-specific targeting: identification of cell-selective peptides from combinatorial librariesCurr Opin Chem Biol200041162110679380
   PubMed Web of Science ®Google Scholar
• LaakkonenPVuorinenKHoming peptides as targeted delivery vehiclesIntegr Biol (Camb)201027–832633720657951
   PubMed Web of Science ®Google Scholar
• ZhangXXEdenHSChenXPeptides in cancer nanomedicine: drug carriers, targeting ligands and protease substratesJ Control Release2012159121322056916
   PubMed Web of Science ®Google Scholar
• McGuireMJSamliKNChangYCBrownKCNovel ligands for cancer diagnosis: selection of peptide ligands for identification and isolation of B-cell lymphomasExp Hematol200634444345216569591
   PubMed Web of Science ®Google Scholar
• LaakkonenPAkermanMEBiliranHAntitumor activity of a homing peptide that targets tumor lymphatics and tumor cellsProc Natl Acad Sci U S A2004101259381938615197262
   PubMed Web of Science ®Google Scholar
• KoivunenEWangBRuoslahtiEPhage libraries displaying cyclic peptides with different ring sizes: ligand specificities of the RGD-directed integrinsBiotechnology (N Y)19951332652709634769
   PubMedGoogle Scholar
• PasqualiniRKoivunenERuoslahtiEA peptide isolated from phage display libraries is a structural and functional mimic of an RGD-binding site on integrinsJ Cell Biol19951305118911967657703
   PubMed Web of Science ®Google Scholar
• SugaharaKNTeesaluTKarmaliPPTissue-penetrating delivery of compounds and nanoparticles into tumorsCancer Cell200916651052019962669
   PubMed Web of Science ®Google Scholar
• WangKZhangXZhangLDevelopment of biodegradable polymeric implants of RGD-modified PEG-PAMAM-DOX conjugates for long-term intratumoral releaseDrug Deliv Epub3272014
   Web of Science ®Google Scholar
• JoyceJALaakkonenPBernasconiMBergersGRuoslahtiEHanahanDStage-specific vascular markers revealed by phage display in a mouse model of pancreatic islet tumorigenesisCancer Cell20034539340314667506
   PubMed Web of Science ®Google Scholar
• HoffmanJAGiraudoESinghMProgressive vascular changes in a transgenic mouse model of squamous cell carcinomaCancer Cell20034538339114667505
   PubMed Web of Science ®Google Scholar
• MeiringMSLitthauerDHarsfalviJvan WykVBadenhorstPNKotzeHFIn vitro effect of a thrombin inhibition peptide selected by phage display technologyThromb Res2002107636537112565725
   PubMed Web of Science ®Google Scholar
• SamliKNMcGuireMJNewgardCBJohnstonSABrownKCPeptide-mediated targeting of the islets of LangerhansDiabetes20055472103210815983211
   PubMed Web of Science ®Google Scholar
• OyamaTSykesKFSamliKNMinnaJDJohnstonSABrownKCIsolation of lung tumor specific peptides from a random peptide library: generation of diagnostic and cell-targeting reagentsCancer Lett2003202221923014643452
   PubMed Web of Science ®Google Scholar
• LiZZhaoRWuXIdentification and characterization of a novel peptide ligand of epidermal growth factor receptor for targeted delivery of therapeuticsFASEB J200519141978198516319141
   PubMed Web of Science ®Google Scholar
• EskensFADumezHHoekstraRPhase I and pharmacokinetic study of continuous twice weekly intravenous administration of Cilengitide (EMD 121974), a novel inhibitor of the integrins alphavbeta3 and alphavbeta5 in patients with advanced solid tumoursEur J Cancer200339791792612706360
   PubMed Web of Science ®Google Scholar
• KragDNShuklaGSShenGPSelection of tumor-binding ligands in cancer patients with phage display librariesCancer Res200666157724773316885375
   PubMed Web of Science ®Google Scholar
• MacDonaldTJStewartCFKocakMPhase I clinical trial of cilengitide in children with refractory brain tumors: Pediatric Brain Tumor Consortium Study PBTC-012J Clin Oncol200826691992418281665
   PubMed Web of Science ®Google Scholar
• GregorcVSantoroABennicelliEPhase Ib study of NGR-hTNF, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumoursBr J Cancer2009101221922419568235
   PubMed Web of Science ®Google Scholar
• HuangGZhouZSrinivasanRAffinity manipulation of surface-conjugated RGD peptide to modulate binding of liposomes to activated plateletsBiomaterials200829111676168518192005
   PubMed Web of Science ®Google Scholar
• AlloattiDGianniniGVesciLCamptothecins in tumor homing via an RGD sequence mimeticBioorg Med Chem Lett201222206509651222959246
   PubMed Web of Science ®Google Scholar
• YanoAOnozukaAMatinKImaiSHanadaNNisizawaTRGD motif enhances immunogenicity and adjuvanicity of peptide antigens following intranasal immunizationVaccine200322223724314615151
   PubMed Web of Science ®Google Scholar
• YoungLaiEVTodoroffECThe pituitary gonadotropin-releasing hormone (GnRH) receptor of the female rabbit: characterization and developmental aspectsCan J Physiol Pharmacol19927012163916461338713
   PubMed Web of Science ®Google Scholar
• HeYZhangLSongCLuteinizing hormone-releasing hormone receptor-mediated delivery of mitoxantrone using LHRH analogs modified with PEGylated liposomesInt J Nanomedicine2010569770520957221
   PubMed Web of Science ®Google Scholar
• LiYCozziPJTargeting uPA/uPAR in prostate cancerCancer Treat Rev200733652152717658220
   PubMed Web of Science ®Google Scholar
• PlougMOstergaardSGardsvollHPeptide-derived antagonists of the urokinase receptor. Affinity maturation by combinatorial chemistry, identification of functional epitopes, and inhibitory effect on cancer cell intravasationBiochemistry20014040121571216811580291
   PubMed Web of Science ®Google Scholar
• KnorSSatoSHuberTDevelopment and evaluation of peptidic ligands targeting tumour-associated urokinase plasminogen activator receptor (uPAR) for use in alpha-emitter therapy for disseminated ovarian cancerEur J Nucl Med Mol Imaging2008351536417891393
   PubMed Web of Science ®Google Scholar
• LanderESLintonLMBirrenBInitial sequencing and analysis of the human genomeNature2001409682286092111237011
   PubMed Web of Science ®Google Scholar
• KajanderTCortajarenaALReganLConsensus design as a tool for engineering repeat proteinsMethods Mol Biol200634015117016957336
   PubMedGoogle Scholar
• LeaderBBacaQJGolanDEProtein therapeutics: a summary and pharmacological classificationNat Rev Drug Discov200871213918097458
   PubMed Web of Science ®Google Scholar
• ZahndCWylerESchwenkJMA designed ankyrin repeat protein evolved to picomolar affinity to Her2J Mol Biol200736941015102817466328
   PubMed Web of Science ®Google Scholar
• StumppMTBinzHKAmstutzPDARPins: a new generation of protein therapeuticsDrug Discov Today20081315–1669570118621567
   PubMed Web of Science ®Google Scholar
• WetzelSKSettanniGKenigMBinzHKPluckthunAFolding and unfolding mechanism of highly stable full-consensus ankyrin repeat proteinsJ Mol Biol2008376124125718164721
   PubMed Web of Science ®Google Scholar
• BinzHKAmstutzPKohlAHigh-affinity binders selected from designed ankyrin repeat protein librariesNat Biotechnol200422557558215097997
   PubMed Web of Science ®Google Scholar
• SchweizerARusertPBerlingerLCD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristicsPLoS Pathog200847e100010918654624
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.govA Phase I/II, Open-label, Single Ascending Dose Study Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of Intravitreal MP0112 in Patients With Diabetic Macular Edema (DME) Available from: http://clinicaltrials.gov/show/NCT01042678Accessed January 1, 2010
   Google Scholar
• JanasTJanasTThe selection of aptamers specific for membrane molecular targetsCell Mol Biol Lett2011161253920585890
   PubMed Web of Science ®Google Scholar
• JayasenaSDAptamers: an emerging class of molecules that rival antibodies in diagnosticsClin Chem19994591628165010471678
   PubMed Web of Science ®Google Scholar
• MissailidisSThomaidouDBorbasKEPriceMRSelection of aptamers with high affinity and high specificity against C595, an anti-MUC1 IgG3 monoclonal antibody, for antibody targetingJ Immunol Methods20052961–2456215680150
   PubMed Web of Science ®Google Scholar
• KeefeADCloadSTSELEX with modified nucleotidesCurr Opin Chem Biol200812444845618644461
   PubMed Web of Science ®Google Scholar
• DuaPKimSLeeDKNucleic acid aptamers targeting cell-surface proteinsMethods201154221522521300154
   PubMed Web of Science ®Google Scholar
• IresonCRKellandLRDiscovery and development of anticancer aptamersMol Cancer Ther20065122957296217172400
   PubMed Web of Science ®Google Scholar
• SundaramPKurniawanHByrneMEWowerJTherapeutic RNA aptamers in clinical trialsEur J Pharm Sci2013481–225927123142634
   PubMed Web of Science ®Google Scholar
• CibielAPestourieCDucongeFIn vivo uses of aptamers selected against cell surface biomarkers for therapy and molecular imagingBiochimie20129471595160622738730
   PubMed Web of Science ®Google Scholar
• SapraPAllenTMLigand-targeted liposomal anticancer drugsProg Lipid Res200342543946212814645
   PubMed Web of Science ®Google Scholar
• AntonyACThe biological chemistry of folate receptorsBlood19927911280728201586732
   PubMed Web of Science ®Google Scholar
• WeitmanSDLarkRHConeyLRDistribution of the folate receptor GP38 in normal and malignant cell lines and tissuesCancer Res19925212339634011596899
   PubMed Web of Science ®Google Scholar
• AiJXuYLiDLiuZWangEFolic acid as delivery vehicles: targeting folate conjugated fluorescent nanoparticles to tumors imagingTalanta2012101323723158287
   PubMed Web of Science ®Google Scholar
• ChenCKeJZhouXEStructural basis for molecular recognition of folic acid by folate receptorsNature2013500746348648923851396
   PubMed Web of Science ®Google Scholar
• McHughMChengYCDemonstration of a high affinity folate binder in human cell membranes and its characterization in cultured human KB cellsJ Biol Chem1979254221131211318500647
   PubMed Web of Science ®Google Scholar
• LeeRJLowPSDelivery of liposomes into cultured KB cells via folate receptor-mediated endocytosisJ Biol Chem19942695319832048106354
   PubMed Web of Science ®Google Scholar
• WangSLeeRJCauchonGGorensteinDGLowPSDelivery of anti-sense oligodeoxyribonucleotides against the human epidermal growth factor receptor into cultured KB cells with liposomes conjugated to folate via polyethylene glycolProc Natl Acad Sci U S A1995928331833227724560
   PubMed Web of Science ®Google Scholar
• LeamonCPLowPSDelivery of macromolecules into living cells: a method that exploits folate receptor endocytosisProc Natl Acad Sci U S A19918813557255762062838
   PubMed Web of Science ®Google Scholar
• GabizonAHorowitzATGorenDTargeting folate receptor with folate linked to extremities of poly(ethylene glycol)-grafted liposomes: in vitro studiesBioconjug Chem199910228929810077479
   PubMed Web of Science ®Google Scholar
• GabizonAHorowitzATGorenDTzemachDShmeedaHZalipskySIn vivo fate of folate-targeted polyethylene-glycol liposomes in tumor-bearing miceClin Cancer Res20039176551655914695160
   PubMed Web of Science ®Google Scholar
• LeamonCPCooperSRHardeeGEFolate-liposome-mediated antisense oligodeoxynucleotide targeting to cancer cells: evaluation in vitro and in vivoBioconjug Chem200314473874712862426
   PubMed Web of Science ®Google Scholar
• TurkMJBreurGJWidmerWRFolate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritisArthritis Rheum20024671947195512124880
   PubMed Web of Science ®Google Scholar
• VarkiABiological roles of oligosaccharides: all of the theories are correctGlycobiology199332971308490246
   PubMed Web of Science ®Google Scholar
• BiesCLehrCMWoodleyJFLectin-mediated drug targeting: history and applicationsAdv Drug Deliv Rev200456442543514969751
   PubMed Web of Science ®Google Scholar
• LepeniesBLeeJSonkariaSTargeting C-type lectin receptors with multivalent carbohydrate ligandsAdv Drug Deliv Rev20136591271128123727341
   PubMed Web of Science ®Google Scholar
• ArnaizBMartinez-AvilaOFalcon-PerezJMPenadesSCellular uptake of gold nanoparticles bearing HIV gp120 oligomannosidesBioconjug Chem201223481482522433013
   PubMed Web of Science ®Google Scholar
• Ribeiro-VianaRSanchez-NavarroMLuczkowiakJVirus-like glycodendrinanoparticles displaying quasi-equivalent nested polyvalency upon glycoprotein platforms potently block viral infectionNat Commun20123130323250433
   PubMed Web of Science ®Google Scholar
• LuczkowiakJMunozASanchez-NavarroMGlycofullerenes inhibit viral infectionBiomacromolecules201314243143723281578
   PubMed Web of Science ®Google Scholar
• Diaz-MoscosoAGuilloteauNBienvenuCMannosyl-coated nanocomplexes from amphiphilic cyclodextrins and pDNA for site-specific gene deliveryBiomaterials201132297263727321741082
   PubMed Web of Science ®Google Scholar
• BarrientosAGde la FuenteJMJimenezMModulating glycosidase degradation and lectin recognition of gold glyconanoparticlesCarbohydr Res2009344121474147819501815
   PubMed Web of Science ®Google Scholar
• KratzFBeyerURothTTransferrin conjugates of doxorubicin: synthesis, characterization, cellular uptake, and in vitro efficacyJ Pharm Sci19988733383469523988
   PubMed Web of Science ®Google Scholar
• Bou-AbdallahFTerpstraTRThe thermodynamic and binding properties of the transferrins as studied by isothermal titration calorimetryBiochim Biophys Acta20121820331832521843602
   PubMed Web of Science ®Google Scholar
• DanielsTRBernabeuERodriguezJAThe transferrin receptor and the targeted delivery of therapeutic agents against cancerBiochim Biophys Acta20121820329131721851850
   PubMed Web of Science ®Google Scholar
• SinghMAtwalHMicetichRTransferrin directed delivery of adriamycin to human cellsAnticancer Res1998183A142314279673350
   PubMed Web of Science ®Google Scholar
• BercziABarabasKSizenskyJAFaulkWPAdriamycin conjugates of human transferrin bind transferrin receptors and kill K562 and HL60 cellsArch Biochem Biophys199330013563638424669
   PubMed Web of Science ®Google Scholar
• LubganDJozwiakZGrabenbauerGGDistelLVDoxorubicin-transferrin conjugate selectively overcomes multidrug resistance in leukaemia cellsCell Mol Biol Lett200914111312718850074
   PubMed Web of Science ®Google Scholar
• RasoVBasalaMA highly cytotoxic human transferrin-ricin A chain conjugate used to select receptor-modified cellsJ Biol Chem19842592114311496319379
   PubMed Web of Science ®Google Scholar
• MannJFStiehDKleinKTransferrin conjugation confers mucosal molecular targeting to a model HIV-1 trimeric gp140 vaccine antigenJ Control Release2012158224024922119743
   PubMed Web of Science ®Google Scholar
• HuangRKeWLiuYJiangCPeiYThe use of lactoferrin as a ligand for targeting the polyamidoamine-based gene delivery system to the brainBiomaterials200829223824617935779
   PubMed Web of Science ®Google Scholar
• YeYSunYZhaoHA novel lactoferrin-modified beta-cyclodextrin nanocarrier for brain-targeting drug deliveryInt J Pharm2013458111011724126038
   PubMedGoogle Scholar
• MeilingerMHaumerMSzakmaryKARemoval of lactoferrin from plasma is mediated by binding to low density lipoprotein receptor-related protein/alpha 2-macroglobulin receptor and transport to endosomesFEBS Lett1995360170747533106
   PubMed Web of Science ®Google Scholar
• BennattDJMcAbeeDDIdentification and isolation of a 45-kDa calcium-dependent lactoferrin receptor from rat hepatocytesBiochemistry19973627835983669204883
   PubMed Web of Science ®Google Scholar
• McAbeeDDJiangXWalshKBLactoferrin binding to the rat asialoglycoprotein receptor requires the receptor’s lectin propertiesBiochem J2000348Pt 111311710794721
   PubMedGoogle Scholar
• WeiMXuYZouQHepatocellular carcinoma targeting effect of PEGylated liposomes modified with lactoferrinEur J Pharm Sci201246313114122369856
   PubMed Web of Science ®Google Scholar
• CoutinhoMFPrataMJAlvesSMannose-6-phosphate pathway: a review on its role in lysosomal function and dysfunctionMol Genet Metab2012105454255022266136
   PubMed Web of Science ®Google Scholar
• TongPYGregoryWKornfeldSLigand interactions of the cation-independent mannose 6-phosphate receptor. The stoichiometry of mannose 6-phosphate bindingJ Biol Chem198926414796279692542254
   PubMed Web of Science ®Google Scholar
• JeanjeanAGary-BoboMNirdePLeirisSGarciaMMorereASynthesis of new sulfonate and phosphonate derivatives for cation-independent mannose 6-phosphate receptor targetingBioorg Med Chem Lett200818236240624318929485
   PubMed Web of Science ®Google Scholar
• ZaccheoOJPrinceSNMillerDMKinetics of insulin-like growth factor II (IGF-II) interaction with domain 11 of the human IGF-II/mannose 6-phosphate receptor: function of CD and AB loop solvent-exposed residuesJ Mol Biol2006359240342116631789
   PubMed Web of Science ®Google Scholar
• GururanganSFriedmanHSInnovations in design and delivery of chemotherapy for brain tumorsNeuroimaging Clin N Am200212458359712687913
   PubMed Web of Science ®Google Scholar
• AllenDDGeldenhuysWJMolecular modeling of blood-brain barrier nutrient transporters: in silico basis for evaluation of potential drug delivery to the central nervous systemLife Sci200678101029103316126231
   PubMed Web of Science ®Google Scholar
• AdrianJEKampsJAPoelstraKScherphofGLMeijerDKKanedaYDelivery of viral vectors to hepatic stellate cells in fibrotic livers using HVJ envelopes fused with targeted liposomesJ Drug Target2007151758217365276
   PubMed Web of Science ®Google Scholar
• MillsJNeedhamDTargeted drug deliveryExpert Opin Ther Patents1999914991513
   Web of Science ®Google Scholar
• BaeYHParkKTargeted drug delivery to tumors: myths, reality and possibilityJ Control Release2011153319820521663778
   PubMed Web of Science ®Google Scholar
• MatsumuraYOdaTMaedaHGeneral mechanism of intratumor accumulation of macromolecules: advantage of macromolecular therapeuticsGan To Kagaku Ryoho1987143 Pt 2821829 Japanese2952066
   PubMedGoogle Scholar
• EmanuelNKedarEBolotinEMSmorodinskyNIBarenholzYTargeted delivery of doxorubicin via sterically stabilized immunoliposomes: pharmacokinetics and biodistribution in tumor-bearing micePharm Res19961368618688792423
   PubMed Web of Science ®Google Scholar
• CallGBOlsonJMChenJGenomewide clonal analysis of lethal mutations in the Drosophila melanogaster eye: comparison of the X chromosome and autosomesGenetics2007177268969717720911
   PubMed Web of Science ®Google Scholar
• StrebhardtKUllrichAPaul Ehrlich’s magic bullet concept: 100 years of progressNat Rev Cancer20088647348018469827
   PubMed Web of Science ®Google Scholar
• AllenTMCullisPRLiposomal drug delivery systems: from concept to clinical applicationsAdv Drug Deliv Rev2013651364823036225
   PubMed Web of Science ®Google Scholar
• OldhamRKDillmanROMonoclonal antibodies in cancer therapy: 25 years of progressJ Clin Oncol200826111774177718398141
   PubMed Web of Science ®Google Scholar
• ElbakriANelsonPNAbu OdehROThe state of antibody therapyHum Immunol201071121243125020849901
   PubMed Web of Science ®Google Scholar
• OliveiraSHeukersRSornkomJKokRJvan Bergen En HenegouwenPMTargeting tumors with nanobodies for cancer imaging and therapyJ Control Release2013172360761724035975
   PubMed Web of Science ®Google Scholar
• KaminskiMSZelenetzADPressOWPivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomasJ Clin Oncol200119193918392811579112
   PubMed Web of Science ®Google Scholar
• SieversELLarsonRAStadtmauerEAEfficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapseJ Clin Oncol200119133244325411432892
   PubMed Web of Science ®Google Scholar
• WitzigTEGordonLICabanillasFRandomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphomaJ Clin Oncol200220102453246312011122
   PubMed Web of Science ®Google Scholar
• NobleGTStefanickJFAshleyJDKiziltepeTBilgicerBLigand-targeted liposome design: challenges and fundamental considerationsTrends Biotechnol2014321324524210498
   PubMed Web of Science ®Google Scholar
• KirpotinDBDrummondDCShaoYAntibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal modelsCancer Res200666136732674016818648
   PubMed Web of Science ®Google Scholar
• SawantRRTorchilinVPChallenges in development of targeted liposomal therapeuticsAAPS J201214230331522415612
   PubMed Web of Science ®Google Scholar
• YokotaTMilenicDEWhitlowMSchlomJRapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin formsCancer Res19925212340234081596900
   PubMed Web of Science ®Google Scholar
• KuaiRYuanWLiWTargeted delivery of cargoes into a murine solid tumor by a cell-penetrating peptide and cleavable poly(ethylene glycol) comodified liposomal delivery system via systemic administrationMol Pharm2011862151216121981683
   PubMedGoogle Scholar
• Quintero-HernandezVJuarez-GonzalezVROrtiz-LeonMSanchezRPossaniLDBecerrilBThe change of the scFv into the Fab format improves the stability and in vivo toxin neutralization capacity of recombinant antibodiesMol Immunol20074461307131516814388
   PubMed Web of Science ®Google Scholar
• AhmadZAYeapSKAliAMHoWYAlitheenNBHamidMscFv antibody: principles and clinical applicationClin Dev Immunol2012201298025022474489
   PubMed Web of Science ®Google Scholar
• PadroTBiekerRRuizSOverexpression of vascular endothelial growth factor (VEGF) and its cellular receptor KDR (VEGFR-2) in the bone marrow of patients with acute myeloid leukemiaLeukemia20021671302131012094254
   PubMed Web of Science ®Google Scholar
• KokkonenNUlibarriIFKauppilaAHypoxia upregulates carcinoembryonic antigen expression in cancer cellsInt J Cancer2007121112443245017657737
   PubMed Web of Science ®Google Scholar
• Savage LaboratoriesDigiFab digoxin immune Fab (ovine) Available from: http://www.savagelabs.com/index.htmAccessed December 23, 2014
   Google Scholar
• KelleyBIndustrialization of mAb production technology: the bioprocessing industry at a crossroadsMAbs20091544345220065641
   PubMed Web of Science ®Google Scholar
• LiMXiaoXZhangWLiuLXiNWangYNanoscale distribution of CD20 on B-cell lymphoma tumour cells and its potential role in the clinical efficacy of rituximabJ Microsc20142541193024499016
   PubMed Web of Science ®Google Scholar
• Carrasco-TrigueroMYiJHDereRImmunogenicity assays for antibody-drug conjugates: case study with ado-trastuzumab emtansineBioanalysis2013591007102323641693
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKJGerberHPNovotnyWDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov20043539140015136787
   PubMed Web of Science ®Google Scholar
• LinTSFlinnIWModaliRFCGR3A and FCGR2A polymorphisms may not correlate with response to alemtuzumab in chronic lymphocytic leukemiaBlood2005105128929115217834
   PubMed Web of Science ®Google Scholar
• RatzingerGReaganJLHellerGBusamKJYoungJWDifferential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantationBlood200310141422142912393688
   PubMed Web of Science ®Google Scholar
• WhiteRRSullengerBARusconiCPDeveloping aptamers into therapeuticsJ Clin Invest2000106892993411032851
   PubMed Web of Science ®Google Scholar
• ChengWWDasDSureshMAllenTMExpression and purification of two anti-CD19 single chain Fv fragments for targeting of liposomes to CD19-expressing cellsBiochim Biophys Acta200717681212917046711
   PubMed Web of Science ®Google Scholar
• RadomFJurekPMMazurekMPOtlewskiJJelenFAptamers: molecules of great potentialBiotechnol Adv20133181260127423632375
   PubMed Web of Science ®Google Scholar
• JavierDJNitinNLevyMEllingtonARichards-KortumRAptamer-targeted gold nanoparticles as molecular-specific contrast agents for reflectance imagingBioconjug Chem20081961309131218512972
   PubMed Web of Science ®Google Scholar
• Jimenez-BarberoJDragoniEVenturiCAlpha-O-linked glycopeptide mimetics: synthesis, conformation analysis, and interactions with viscumin, a galactoside-binding model lectinChemistry20091540104231043119746469
   PubMed Web of Science ®Google Scholar
• BennettMJLebronJABjorkmanPJCrystal structure of the hereditary haemochromatosis protein HFE complexed with transferrin receptorNature20004036765465310638746
   PubMed Web of Science ®Google Scholar